Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, Credit Suisse, SVB, and Amgen and Encourages Investors to Contact the Firm
March 17, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
DEADLINE ALERT for SIVB, AMGN, and SBNY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
March 17, 2023 12:00 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 17, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
AMGN ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
March 15, 2023 18:01 ET
|
The Rosen Law Firm PA
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Amgen...
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amgen Inc. (NASDAQ: AMGN)
March 15, 2023 16:00 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in Amgen Inc.? If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your...
CHEMOCENTRYX, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CCXI and Encourages Investors to Contact the Firm
August 07, 2022 20:05 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 07, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
BeiGene Begins Commercializing XGEVA® (Denosumab) in China
June 30, 2020 19:30 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
January 02, 2020 08:15 ET
|
BeiGene, LTD.
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
BeiGene Announces Global Strategic Oncology Collaboration with Amgen
October 31, 2019 16:00 ET
|
BeiGene, LTD.
• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China • Companies to Jointly Develop 20 Amgen Oncology Pipeline...